China - World Leader.
Answered by
Ridzwan Abdul Rahman
Nov 21
Are Chinese covid vaccines made by China now considered as useless given the Chinese government is now buying license for 1 billion doses of Pfizer vaccine via Sinopharm aka FOSUN pharma?
There is nothing great about the Pfizer vaccine, as confirmed by Israel:

Israel says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness
Pfizer's and BioNTech's Covid-19 vaccine is just 39% effective against delta in Israel, but still provides strong protection against severe illness and hospitalization.
https://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html
Mayo Clinic found Pfizer's effectiveness at 42% against the Delta variant.

Medical Study Shows that Pfizer Shot was Only 42% Effective Against COVID Infection in July 2021
Medical Study Shows that Pfizer Shot was Only 42% Effective Against COVID Infection in July 2021 Posted on 08/11/2021 In a study titled, “Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence�
��, that was posted on medRxiv, raises concerns about the mRNA vaccines’ effectiveness against Delta (Indian) variant, particularly Pfizer’s COVID shots. The study found the Pfizer vaccine was only 42% effective against infection in July 2021, when
the Delta variant was dominant. The study has not been peer-reviewed. The study found that the Moderna vaccine was 86% effective against infection over the study period, and Pfizer’s was 76%. Moderna’s vaccine was 92% effective against
hospitalization and Pfizer’s was 85%. Moderna was 76% effective against COVID infection, and Pfizer was only 42% effective for the July time period. STUDY ABSTRACT: Although clinical trials and real-world studies have affirmed the effectiveness and
safety of the FDA-authorized COVID-19 vaccines, reports of breakthrough infections and persistent emergence of new variants highlight the need to vigilantly monitor the effectiveness of these vaccines. Here we compare the effectiveness of two full-length
Spike protein-encoding mRNA vaccines from Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) in the Mayo Clinic Health System over time from January to July 2021, during which either the Alpha or Delta variant was highly prevalent. We defined cohorts of
vaccinated and unvaccinated individuals from Minnesota (n = 25,589 each) matched on age, sex, race, history of prior SARS-CoV-2 PCR testing, and date of full vaccination. Both vaccines were highly effective during this study period against SARS-CoV-2
infection (mRNA-1273: 86%, 95%CI: 81-90.6%; BNT162b2: 76%, 95%CI: 69-81%) and COVID-19 associated hospitalization (mRNA-1273: 91.6%, 95% CI: 81-97%; BNT162b2: 85%, 95% CI: 73-93%). However, in July, the effectiveness against infection was considerably
lower for mRNA-1273 (76%, 95% CI: 58-87%) with an even more pronounced reduction in effectiveness for BNT162b2 (42%, 95% CI: 13-62%). Notably, the Delta variant prevalence in Minnesota increased from 0.7% in May to over 70% in July whereas the Alpha
variant prevalence decreased from 85% to 13% over the same time period. Comparing rates of infection between matched individuals fully vaccinated with mRNA-1273 versus BNT162b2 across Mayo Clinic Health System sites in multiple states (Minnesota,
Wisconsin, Arizona, Florida, and Iowa), mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the
risk of infection in July after full vaccination with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62). Our observational study highlights that while both mRNA COVID-19 vaccines strongly protect ag
https://www.swfinstitute.org/news/87813/medical-study-shows-that-pfizer-shot-was-only-42-effective-against-covid-infection-in-july-2021
This explains why the number of daily cases in the US has gone up again to more than a hundred thousand new cases per day, after dropping to about only 8 thousand cases per day in early June.

It turns out the Sinovac is much better at fighting the Delta variant that is now common:

Guangzhou Center for Disease Control and Prevention Chinese epidemiologist lead researcher Zhong Nanshan found that two shots of the vaccine provided an efficacy of 59% (six out of 10 patients) against COVID-19 caused by the Delta variant, 70.2% (seven
out of 10 patients) against a moderate form of the disease and 100% against severe cases.

- Guangzhou’s Real-World Study Shows Sinovac Effective against Delta Variant Opinions on topical issues from thought leaders, columnists and editors. A recent research on the effectiveness of two doses of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) for COVID-19 vaccine conducted in Guangzhou, China, has proven
that it provides sufficient protection against the deadly spread of the Delta variant worldwide. Guangzhou Center for Disease Control and Prevention Chinese epidemiologist lead researcher Zhong Nanshan found that two shots of the vaccine provided an
efficacy of 59% (six out of 10 patients) against COVID-19 caused by the Delta variant, 70.2% (seven out of 10 patients) against a moderate form of the disease and 100% against severe cases. This implies that the vaccine is more effective against moderate
COVID-19 than mild COVID-19. In this regard, the research also exceeded the threshold decided by the World Health Organisation (WHO) to reach the standard that any vaccine for SARS-CoV-2 must achieve the efficacy of 50%. The research polled data from 628
participants, including 153 COVID-19 patients infected by the Delta variant and 475 close contact cases in the city. The patients were 18 to 59 years old. Of them, 10 had critical symptoms, six had severe symptoms, 105 had moderate symptoms, and 32 had
mild symptoms. Two inactivated vaccines, CoronaVac manufactured by Sinovac Biotech Ltd and the China National Biotec Group SARS-CoV-2 vaccine, were chosen by researchers to measure the effectiveness against the Delta strain among the patients. Test for
effectiveness The effectiveness of the vaccines was determined using a test-negative case-control design, a popular method for evaluating vaccine efficacy. The vaccines have also been adopted for mass vaccination within mainland China. The severity or
mildness of the COVID-19 symptoms was categorised based on the observation of patients. Those without any external signs were classified as mild COVID-19 patients; however, those with respiratory symptoms such as fever and imaging characteristics of
pneumonia were grouped as moderate COVID-19 patients. Patients with oxygenation index <300 mmHg, resting oxygen saturation <93%, and respiratory rate >30/min were categorised as severe. Those experiencing respiratory failure and requiring mechanical
ventilation, shock or other organ failure requiring admission to the ICU were classified as critical COVID-19 patients. The research also revealed that those patients vaccinated with a single vaccine dose also showed some degree of protection against the
COVID-19 disease. The effectiveness of a single dose of the vaccine was 13.8%. The study found that none of the 16 cases with critical and severe COVID-19 had been vaccinated with SARS-CoV-2 vaccines. In the same research, the scientists also discovered
that the vaccine effectiveness was higher in females and people in the age group of 40-59 (with an efficacy rate of 72.5%) compared to males and those with moderate COVID-19. This shows the need to further strengthen vacc
https://www.bernama.com/en/thoughts/news.php?id=2002712
That’s 59% for Sinovac against 39% for Pfizer.

Concerning Fosun and BioNTech, it is purely a business deal between two companies. It has nothing to do with the Government of China. Fosun figured that there would be people who might want to use the BioNTech vaccine because there are many Westerners in
China, and there is pro-West Taiwan.

So Fosun and BioNTech came up with a plan to manufacture some BioNTech vaccines in China through a 50–50 JV company between Fosun and BioNTech. This agreement was made in May this year. It has nothing to do with Pfizer because the vaccine was developed
by BioNTech with no help from Pfizer. Pfizer is only marketing the vaccine.

It has nothing to do with the effectiveness of any vaccine.

BioNTech, Fosun Pharma eye 1B doses of COVID-19 vaccine capacity with new China JV
As BioNTech makes inroads with its COVID-19 vaccine in Western countries under a partnership with Pfizer, the German biotech is bringing its work in China to the next level with a joint venture with licensing partner Fosun Pharma. The goal is to have
manufacturing capacity of up to 1 billion doses a year. https://www.fiercepharma.com/manufacturing/biontech-fosun-pharma-eye-1b-doses-covid-19-vaccine-capacity-new-china-jv

--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)